The total return over the past 12 months is +11.06% vs. +16.94% for the S&P 500. So far it's up -23.08% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | (1.86%) | (34.65%) | (42.73%) | (33.59%) | (39.35%) | (45.35%) |
| Total Return CAGR | +11.06% | (33.49%) | (42.13%) | (33.25%) | (39.15%) | (45.21%) |
| Revenue CAGR | (77.12%) | (31.01%) | N/A | N/A | N/A | N/A |
| Net Income CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
Marker Therapeutics, Inc. (MRKR)
| Year | Start price | End price | MRKR Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $1.49 | $1.06 | (23.08%) | +14.51% | (37.59%) |
| 2025 | $3.11 | $1.49 | (53.57%) | +17.72% | (71.29%) |
| 2024 | $5.50 | $3.11 | (42.86%) | +24.89% | (67.75%) |
| 2023 | $2.66 | $5.50 | +104.17% | +26.19% | +77.98% |
| 2022 | $9.50 | $2.66 | (71.76%) | (18.17%) | (53.59%) |
| 2021 | $14.50 | $9.50 | (34.62%) | +28.74% | (63.36%) |
| 2020 | $28.80 | $14.50 | (49.61%) | +18.37% | (67.98%) |
| 2019 | $55.50 | $28.80 | (48.09%) | +31.22% | (79.31%) |
| 2018 | $39.20 | $55.50 | +41.60% | (4.56%) | +46.16% |
| 2017 | $38.80 | $39.20 | +0.86% | +21.70% | (20.84%) |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
